🇺🇸 FDA

Company profile · Sponsor

Corvus

Corvus Pharmaceuticals

CRVS · NYSE pharma SOUTH SAN FRANCISCO, CA, USA
Pipeline
9
Drugs
0
Patents
8

Quick answer

Corvus (CRVS) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker CRVS
Exchange NYSE
Company type pharma
Headquarters SOUTH SAN FRANCISCO, CA, USA
SEC CIK 0001626971

Pipeline (9)

Search pipeline →

  1. CPI-006 2 mg/kg + SOC

    Corvus

    Covid-19

    phase 3 small molecule terminated

    1 trial

  2. Soquelitinib

    Corvus

    Peripheral T-Cell Lymphoma, Not Otherwise Specified

    phase 3 small molecule active

    1 trial

  3. Soquelitinib

    Corvus

    Atopic Dermatitis

    phase 2 small molecule active

    2 trials

  4. CPI-006

    Corvus

    Non-Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  5. CPI-006

    Corvus

    COVID-19

    phase 1 small molecule completed

    1 trial

  6. CPI-444 Capsules

    Corvus

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  7. CPI-818

    Corvus

    T-cell Lymphoma

    phase 1 small molecule active

    1 trial

  8. Ciforadenant

    Corvus

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  9. Ciforadenant

    Corvus

    Renal Cell Cancer

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12351644

    Anti-CD73 antibodies

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12174192

    Methods for detecting and treating cancers having adenosine pathway activation

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12116635

    Methods for detecting and treating cancers having adenosine pathway activation

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12023337

    Methods of treating cancer

    Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11897874

    Compounds and methods for modulating Interleukin-2-inducible T-cell kinase

    Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11859007

    Humanized anti-CD73 antibodies

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11266649

    Pharmaceutical formulations

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11254686

    Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Corvus?

Corvus (CRVS) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Corvus sponsor?

We track 9 ClinicalTrials.gov-linked programs for Corvus, including CPI-006 2 mg/kg + SOC and 8 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Corvus company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.